Endostatin inhibits bradykinin-induced cardiac contraction

Area of Science:

• Cardiovascular Physiology
• Molecular Cardiology
• Extracellular Matrix Biology

Background:

• Endogenous extracellular matrix fragments, like endostatin, exhibit diverse biological activities.
• Elevated endostatin levels are observed in cardiac pathologies such as hypertrophy and myocardial infarction.
• The specific impact of endostatin on cardiac contractility remains largely unelucidated.

Purpose of the Study:

• To investigate the effect of endostatin on bradykinin-induced atrial contraction.
• To explore the underlying mechanisms of endostatin's influence on cardiac electrophysiology.

Main Methods:

• Isometric contractile force of isolated mouse left atria was measured.
• Voltage-dependent calcium currents in guinea pig ventricular myocytes were assessed using the whole-cell patch-clamp technique.
• Experiments involved treatment with varying concentrations of endostatin and bradykinin.

Main Results:

• Endostatin alone (100-1,000 ng/ml) did not affect basal left atrial contraction.
• Pre-treatment with endostatin (300 ng/ml) significantly attenuated bradykinin (1 µM)-induced atrial contraction.
• Endostatin also significantly inhibited bradykinin-induced voltage-dependent calcium current.

Conclusions:

• Endostatin may reduce bradykinin-stimulated cardiac contraction.
• The inhibitory effect of endostatin on cardiac contraction is potentially mediated by the blockade of voltage-dependent calcium channels.
• These findings offer insights into the role of endostatin in cardiac function and disease.